Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mitrix Bio Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners but 1 distinct art unit, so examiner coordination is required within a common technical classification.
TIWARI, VYOMA SHUBHAM is the busiest examiner, with 1 pending matter. A coordinated response framework can address shared biotechnology issues while allowing separate treatment of each examiner’s positions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 1 | 32.1% | +47.4% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936814 | PLATELET-DERIVED EXTRACELLULAR VESSICLES FOR TREATMENT OF CARDIOGENIC SHOCK AND SEPSIS | TIWARI, VYOMA SHUBHAM | — |
| 18789363 | PLATELET-DERIVED MITOCHONDRIA-CONTAINING EXTRACELLULAR VESICLES FOR USE IN THE TREATMENT OF OCULAR DISORDERS | WEHBE, ANNE MARIE SABRINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936814 | PLATELET-DERIVED EXTRACELLULAR VESSICLES FOR TREATMENT OF CARDIOGENIC SHOCK AND SEPSIS | TIWARI, VYOMA SHUBHAM | — |
| 18789363 | PLATELET-DERIVED MITOCHONDRIA-CONTAINING EXTRACELLULAR VESICLES FOR USE IN THE TREATMENT OF OCULAR DISORDERS | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18936814 | PLATELET-DERIVED EXTRACELLULAR VESSICLES FOR TREATMENT OF CARDIOGENIC SHOCK AND SEPSIS | TIWARI, VYOMA SHUBHAM | 1634 | §101§103§112 | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18789363 | PLATELET-DERIVED MITOCHONDRIA-CONTAINING EXTRACELLULAR VESICLES FOR USE IN THE TREATMENT OF OCULAR DISORDERS | WEHBE, ANNE MARIE SABRINA | 1634 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMitrix Bio Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Vyoma Shubham Tiwari has the most, with 1 of Mitrix Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
